The immunotherapy of cancer has recently achieved unprecedented clinical success in previously untreatable forms of solid malignancy. Elucidation and targeting of inhibitory pathways known as immune checkpoint, which naturally limit the magnitude of specific immunity, has made this possible. Despite the revolutionary success of checkpoint inhibitors at improving cancer outcomes by unleashing latent immunity targeting immunogenic tumors, most people with advanced cancer still fail to respond to treatment. By combining several established technologies in Proprietary combinations, OncoVent is using its technology platform to raise the level of …